Anduril IPO before 2027?

Prediction markets put the probability at 10%: Anduril IPO before 2027. Currently, markets see this as unlikely (10% YES). Polish defense giant PGZ to produce Anduril’s Barracuda cruise missile.

What’s Happening

An anduril ipo before 2027 remains a low-probability event, with the defense-technology firm showing no public signal of a near-term listing as it continues to expand operationally rather than tap public markets. On 6 July 2026, Anduril Industries signed a strategic agreement with Poland's state-run PGZ to assemble and subsequently produce the Barracuda-500M surface-launched cruise missile at the Military Aviation Works No. 2 facility in Bydgoszcz. Deals of this scale — international co-production and MRO partnerships — typically reinforce a growth-and-reinvestment posture that companies fund through private capital, not the disclosure and quarterly scrutiny an IPO imposes. [Janes, Jul 06]

The broader listings backdrop is active but selective. On 8 July 2026, Jeff Bezos' Blue Origin was valued at $130 billion in its first public fundraising round, while MoffettNathanson initiated coverage of SpaceX with a neutral rating — evidence that large aerospace-defense players are securing valuations through private raises rather than debuting on public exchanges. Law firm Latham & Watkins projected its busiest year for US energy IPOs since 2014, having worked on eight new offerings with five or six more anticipated before 2027, per capital-markets partner Ryan Maierson. That pipeline is concentrated in energy and power, not defense-tech, underscoring that an anduril ipo would run against the current sector rotation. [Bloomberg Law, Jul 08]

What matters next is capital-market conditions and Anduril's own funding cadence. Macro strategists flagged that long-term rates remain the key friction in the US economy, a headwind that tightens IPO windows even as BofA's Savita Subramanian described corporate earnings as being "in a really good spot." With Anduril still executing multibillion-dollar production expansions abroad and no S-1 filing on record, a public debut before year-end 2026 would require a compressed timeline that current signals do not support. The near-term path for any anduril ipo hinges on either a fresh private mega-round or a decisive shift in rate expectations. [CNBC, Jul 08]

Traded on Polymarket — $355K Volume

Polymarket prices this at 10c YES with $355K in volume. Moderate liquidity — use limit orders for positions above $1K to avoid moving the price.